Get the Stockscreener App
12.70
0.32%
0.04
After Hours:
12.70
Urogen Pharma Ltd stock is traded at $12.70, with a volume of 269.88K.
It is up +0.32% in the last 24 hours and up +3.67% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$12.66
Open:
$12.4
24h Volume:
269.88K
Relative Volume:
0.49
Market Cap:
$535.93M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-2.7137
EPS:
-4.68
Net Cash Flow:
$-76.57M
1W Performance:
+6.63%
1M Performance:
+3.67%
6M Performance:
-4.22%
1Y Performance:
-1.09%
1-Day Range:
$12.00
$12.78
1-Week Range:
$12.00
$12.90
52-Week Range:
$10.60
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
12.70 | 535.93M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Vestal Point Capital LP Purchases New Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment - Clinical Trials Arena
Financial Review: UroGen Pharma (NASDAQ:URGN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) - Defense World
Great Point Partners LLC Has $9.64 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
JELMYTO shows long-term efficacy in UTUC study - Investing.com India
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO - Business Wire
URGN (UroGen Pharma) GF Value Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) Momentum Rank : 5 (As of Nov. 25, 2024) - GuruFocus.com
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load? - Simply Wall St
RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd - GuruFocus.com
Analysis of GREAT POINT PARTNERS LLC's Recent Transaction in Uro - GuruFocus.com
Analysis of COWEN AND COMPANY, LLC's Strategic Reduction in UroG - GuruFocus.com
RTW INVESTMENTS, LP Acquires Significant Stake in UroGen Pharma Ltd - GuruFocus.com
UroGen Pharma: Choice Based On Near-Term High-Value PDUFA - Seeking Alpha
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business HighlightsURGN Pharmaceuticals, a leading biotech company focused on urothelial and specialty cancers, disclosed its latest financial outcomes for the third quarter ended Septemb - Defense World
UroGen Pharma Reports Q3 Results and Drug Progress - TipRanks
HC Wainwright Forecasts Stronger Earnings for UroGen Pharma - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target - Yahoo Finance
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript - Insider Monkey
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Morgan Stanley's Strategic Acquisition of UroGen Pharma Shares - GuruFocus.com
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - BioSpace
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
UroGen Pharma Ltd (URGN) Q3 2024 Earnings: EPS of ($0.55) and Re - GuruFocus.com
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - Business Wire
(URGN) Investment Analysis - Stock Traders Daily
Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday - MarketBeat
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - BioSpace
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Business Wire
(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
UroGen started at buy by EF Hutton, RTGel technology cited - MSN
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years - Yahoo Finance
UroGen Pharma maintains Outperform stock rating on new drug application By Investing.com - Investing.com Australia
FDA accepts UroGen's NDA for bladder cancer treatment - Investing.com India
When Would Be The Best Time To Buy UroGen Pharma Ltd (NASDAQ: URGN) Stock? - Stocks Register
URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
UroGen Pharma maintains Outperform stock rating on new drug application - Investing.com
UroGen Pharma Ltd (URGN) looking to reclaim success with recent performance - SETE News
UroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from Oppenheimer - MarketBeat
Wesbanco Bank Inc. Buys Shares of 74,400 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment - Pharmaceutical Technology
UroGen Pharma Says FDA Accepts NDA for UGN-102 - Marketscreener.com
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - The Bakersfield Californian
UroGen Pharma Ltd (URGN) is a good investment, but the stock may be undervalued - US Post News
UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
UroGen Pharma (NASDAQ:URGN) Upgraded to "Strong-Buy" by EF Hutton Acquisition Co. I - MarketBeat
EF Hutton initiates UroGen Pharma shares with Buy rating By Investing.com - Investing.com South Africa
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):